Cabozantinib,Nivolumab,Ipilimumab
Exelixis,bms
['nivo', 'triplet,(-triplete)', 'rcc,(-irccs),(-srcc),(-urcc)', ' ipi ']
triplet vs doublet in metastatic rcc . pfs benifit for intermediate risk . not for poor risk . more toxicity? control arm of nivo plus ipi . will we get os benefit? #esmo22 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists